Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages 26-32

  Zahnd, Cindy ^a   Salazar Vizcaya, Luisa ^a   Dufour, Jean François ^b   Müllhaupt, Beat ^d   Wandeler, Gilles ^a,b,c   Kouyos, Roger ^d   Estill, Janne ^a   Bertisch, Barbara ^a,e   Rauch, Andri ^b   Keiser, Olivia ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Cirrhosis; Hepatitis C; Hepatocellular carcinoma; HIV; Mathematical model

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; FALDAPREVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; DECOMPENSATED LIVER CIRRHOSIS; DRUG COST; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUAL BASED POPULATION MODEL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REINFECTION; VIRUS REPLICATION; LIVER CIRRHOSIS; SEXUAL AND GENDER MINORITY;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; SEXUAL AND GENDER MINORITIES;

EID: 84964758707     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.02.030     Document Type: Article

References (52)

1. C. Smith, C.A. Sabin, J.D. Lundgren, R. Thiebaut, R. Weber, M. Law, and et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study Aids 24 2010 1537 1548
2. R. Weber, M. Ruppik, M. Rickenbach, A. Spoerri, H. Furrer, M. Battegay, and et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study HIV Med 14 2013 195 207
3. CDC. HIV and viral hepatitis, [accessed on 02.02.2014] http://www.cdc.gov/hiv/pdf/library-factsheets-HIV-and-viral-Hepatitis.pdf; 2014.
4. H. Hagan, J. Neurer, A.E. Jordan, D.C. Des Jarlais, J. Wu, K. Dombrowski, and et al. Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis Syst Rev 3 2014 31
5. G. Wandeler, T. Gsponer, A. Bregenzer, H.F. Gunthard, O. Clerc, A. Calmy, and et al. Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic Clin Infect Dis 55 2012 1408 1416
6. T. van de Laar, O. Pybus, S. Bruisten, D. Brown, M. Nelson, S. Bhagani, and et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men Gastroenterology 136 2009 1609 1617
7. M. Vogel, E. Page, C. Boesecke, T. Reiberger, C. Schwarze-Zander, S. Mauss, and et al. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals Clin Infect Dis 54 2012 556 559
8. A. Osinusi, D. Kleiner, B. Wood, M. Polis, H. Masur, and S. Kottilil Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection AIDS Patient Care STDS 23 2009 403 406
9. D.S. Fierer, D.T. Dieterich, M.I. Fiel, A.D. Branch, K.M. Marks, D.N. Fusco, and et al. Rapid progression to decompensated cirrhosis, liver transplantation, and death in HIV-infected men after primary HCV infection Clin Infect Dis 56 2012 1038 1043
10. A.M. Hill, J. Saleem, K.A. Heath, and B. Simmons Effects of Sustained Virological Response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection Hepatology 60 2014 55A
11. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, F. Lammert, and et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
12. P. Labarga, J.V. Fernandez-Montero, P. Barreiro, J. Pinilla, E. Vispo, C. de Mendoza, and et al. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy J Viral Hepat 21 2014 475 479
13. H.A. Innes, S.J. Hutchinson, S. Allen, D. Bhattacharyya, P. Bramley, T.E. Delahooke, and et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care Hepatology 54 2011 1547 1558
14. M. Mendeni, E. Foca, D. Gotti, N. Ladisa, G. Angarano, L. Albini, and et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection Clin Infect Dis 52 2011 1164 1173
15. A.A. Chaudhry, M.S. Sulkowski, G. Chander, and R.D. Moore Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort HIV Med 10 2009 133 142
16. P. Labarga, J.V. Fernandez-Montero, C. de Mendoza, P. Barreiro, J. Pinilla, and V. Soriano Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients Antivir Ther 20 2014 329 334
17. F. Bani-Sadr, N. Lapidus, P. Bedossa, C.M. De Boever, C. Perronne, P. Halfon, and et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors Clin Infect Dis 46 2008 768 774
18. M.S. Sulkowski HCV therapy in HIV-infected patients Liver Int 33 2013 63 67
19. M.S. Sulkowski Current management of hepatitis C virus infection in patients with HIV co-infection J Infect Dis 207 2013 S26 S32
20. M. Puoti, R. Rossotti, G. Travi, C. Panzeri, M. Morreale, E. Chiari, and et al. Optimizing treatment in HIV/HCV coinfection Dig Liver Dis 45S5 2013 S355 S362
21. A. Kohli, A. Shaffer, A. Sherman, and S. Kottilil Treatment of hepatitis C: a systematic review JAMA 312 2014 631 640
22. V. Martel-Laferriere, and D.T. Dieterich Treating HCV in HIV 2013: on the cusp of change Liver Int 34 2014 53 59
23. J.R. Rockstroh, and S. Bhagani Managing HIV/hepatitis C co-infection in the era of direct acting antivirals BMC Med 11 2013 234
24. M. Zeremski, A.D. Martinez, and A.H. Talal Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals Clin Infect Dis 58 2014 880 882
25. A. Hill, S. Khoo, J. Fortunak, B. Simmons, and N. Ford Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries Clin Infect Dis 58 2014 928 936
26. EASL recommendations on treatment of hepatitis C 2015 J Hepatol 63 2015 199 236
27. Anthem Health Insurance. [accessed the 23.01.2015 https://www.anthem.com/provider/noapplication/f0/s0/t0/pw-e210963.pdf?na=pharminfo; 2015.
28. Moradpour D, Rauch A, Fehr J, Müllhaupt B. Treatment of chronic hepatitis C- September 2014 Update. http://www.sginf.ch/ssi/images/ssi/news/SASL-SSI-HepC-EOS-Sept2014.pdf; 2014.
29. NICE. Sofosbuvir for treating chronic hepatitis C. https://www.nice.org.uk/guidance/ta330; 2015.
30. P. Kohler, A.J. Schmidt, M. Cavassini, H. Furrer, A. Calmy, M. Battegay, and et al. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV AIDS 29 2015 2509 2515
31. Luisa Salazar Vizcaya NB, Thomas Gsponer. gems: Generalized multistate simulation model. CRAN, R archive: http://cranr-projectorg/web/packages/gems/indexhtml; 2014.
32. N. Blaser, L. Salazar Vizcaya, J. Estill, C. Zahnd, B. Kalesan, M. Egger, and et al. Gems: an R package for simulating from disease progression models J Stat Software 64 2015 1 22
33. E.C. Thomson, E. Nastouli, J. Main, P. Karayiannis, J. Eliahoo, D. Muir, and et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV Aids 23 2009 89 93
34. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
35. M. Sulkowski, S. Pol, J. Mallolas, H. Fainboim, C. Cooper, J. Slim, and et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial Lancet Infect Dis 13 2013 597 605
36. J.A. Mira, S. Garcia-Rey, A. Rivero, I. de los Santos-Gil, L.F. Lopez-Cortes, J.A. Giron-Gonzalez, and et al. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis Clin Infect Dis 55 2012 1719 1726
37. G. Wandeler, M. Schlauri, M.-E. Jaquier, J. Rohrbach, and K.J. Mtzner Incident hepatitis C Virus infections in the swiss HIV cohort study: changes in treatment uptake and outcomes between 1991 and 2013 Open Forum Infect Dis 2 2015 ofv026
38. T.C. Martin, N.K. Martin, M. Hickman, P. Vickerman, E.E. Page, R. Everett, and et al. HCV reinfection incidence and treatment outcome among HIV-positive MSM in London Aids 27 2013 2551 2557
39. Y.A. Lee, and S.L. Friedman Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C? Antiviral Res 107C 2014 23 30
40. S. Maylin, M. Martinot-Peignoux, R. Moucari, N. Boyer, M.P. Ripault, D. Cazals-Hatem, and et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 2008 821 829
41. T. Poynard, J. Moussalli, M. Munteanu, D. Thabut, P. Lebray, M. Rudler, and et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C J Hepatol 59 2013 675 683
42. J.L. Casado, C. Quereda, A. Moreno, M.J. Perez-Elias, P. Marti-Belda, and S. Moreno Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection J Viral Hepat 20 2013 829 837
43. M.S. Cohen, Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour, N. Kumarasamy, and et al. Prevention of HIV-1 infection with early antiretroviral therapy N Engl J Med 365 2011 493 505
44. S. Deuffic-Burban, M. Schwarzinger, D. Obach, V. Mallet, S. Pol, G.P. Pageaux, and et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188) J Hepatol 61 2014 7 14
45. A.J. Leidner, H.W. Chesson, F. Xu, J.W. Ward, P.R. Spradling, and S.D. Holmberg Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease Hepatology 61 2015 1860 1869
46. P. McEwan, T. Ward, H. Bennett, A. Kalsekar, S. Webster, M. Brenner, and et al. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C PLoS One 10 2015 e0117334
47. B.P. Linas, D.M. Barter, J.A. Leff, M. Dilorenzo, B.R. Schackman, C.R. Horsburgh, and et al. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients Aids 28 2014 365 376
48. A.M. Pfeil, O. Reich, I.M. Guerra, S. Cure, F. Negro, B. Mullhaupt, and et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C PLoS One 10 2015 e0126984
49. D.B. Rein, J.S. Wittenborn, B.D. Smith, D.K. Liffmann, and J.W. Ward The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus Clin Infect Dis 61 2015 157 168
50. A.J. van der Meer, H. Wedemeyer, J.J. Feld, J.F. Dufour, S. Zeuzem, B.E. Hansen, and et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population JAMA 312 2014 1927 1928
51. B. Mullhaupt, P. Bruggmann, F. Bihl, S. Blach, D. Lavanchy, H. Razavi, and et al. Modeling the health and economic burden of hepatitis C virus in Switzerland PLoS One 10 2015 e0125214
52. A.A. Shaheen, A.F. Wan, and R.P. Myers FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy Am J Gastroenterol 102 2007 2589 2600